OTCPK:BICX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. More Details


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has BioCorRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BICX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

BICX

1.3%

US Healthcare

1.3%

US Market


1 Year Return

-41.9%

BICX

21.2%

US Healthcare

15.8%

US Market

Return vs Industry: BICX underperformed the US Healthcare industry which returned 21.2% over the past year.

Return vs Market: BICX underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

BICXIndustryMarket
7 Day0%1.3%1.3%
30 Day-14.4%-4.3%-4.1%
90 Day-32.1%-0.7%8.4%
1 Year-41.9%-41.9%22.8%21.2%18.4%15.8%
3 Year-76.5%-76.5%23.8%18.5%38.2%29.0%
5 Year-50.0%-50.0%50.2%39.6%84.9%64.0%

Price Volatility Vs. Market

How volatile is BioCorRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioCorRx undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether BioCorRx is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioCorRx has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BICX's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through BioCorRx regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is BioCorRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioCorRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BICX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioCorRx's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has BioCorRx performed over the past 5 years?

7.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BICX is currently unprofitable.

Growing Profit Margin: BICX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BICX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.5% per year.

Accelerating Growth: Unable to compare BICX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BICX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: BICX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is BioCorRx's financial position?


Financial Position Analysis

Short Term Liabilities: BICX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BICX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BICX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BICX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BICX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BICX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 35.3% each year


Next Steps

Dividend

What is BioCorRx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BICX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BICX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BICX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BICX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BICX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

Brady Granier (48 yo)

4.25yrs

Tenure

US$335,000

Compensation

Mr. Brady James Granier has been the Chief Executive Officer of BioCorRx Inc. since June 17, 2016 and was its President since June 10, 2016. Mr. Granier served as the Chief Operating Officer and Secretary ...


CEO Compensation Analysis

Compensation vs Market: Brady's total compensation ($USD335.00K) is below average for companies of similar size in the US market ($USD601.03K).

Compensation vs Earnings: Brady's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Brady Granier
CEO & Director4.25yrsUS$335.00k1.57%
$ 160.4k
Lourdes Felix
CFO, President & Director7.92yrsUS$320.00k0.65%
$ 66.9k
Thomas Welch
Executive Vice President0.58yrno data0.48%
$ 49.1k
Balbir Brar
Senior Vice President of Drug Developmentno datano datano data
George Fallieras
Medical Consultantno datano datano data

0.6yrs

Average Tenure

50yo

Average Age

Experienced Management: BICX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Brady Granier
CEO & Director4.25yrsUS$335.00k1.57%
$ 160.4k
Lourdes Felix
CFO, President & Director7.92yrsUS$320.00k0.65%
$ 66.9k
Louis Lucido
Independent Director1.5yrsUS$70.00k4.73%
$ 483.3k
Luisa Ingargiola
Independent Director1.5yrsUS$70.00k0.19%
$ 19.4k
Ben Price
Member of Advisory Board6.5yrsno datano data
Kent Emry
Director7yrsUS$70.00k1.5%
$ 153.2k
Mark Sorrentino
Member of Advisory Board6.5yrsno datano data
Richard Haatvedt
Member of Advisory Board6.5yrsno datano data
David Gastfriend
Member of Scientific Advisory Board1.5yrsno datano data
Evgeny Krupitsky
Member of Scientific Advisory Board1.5yrsno datano data
George Woody
Member of Scientific Advisory Board1.5yrsno datano data

4.0yrs

Average Tenure

52.5yo

Average Age

Experienced Board: BICX's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 76%.


Top Shareholders

Company Information

BioCorRx Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioCorRx Inc.
  • Ticker: BICX
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$10.229m
  • Shares outstanding: 5.38m
  • Website: https://www.biocorrx.com

Location

  • BioCorRx Inc.
  • 2390 East Orangewood Avenue
  • Suite 575
  • Anaheim
  • California
  • 92806
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BICXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2011

Biography

BioCorRx Inc., through its subsidiaries, provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers in the United States. It distributes and licenses BioCorR ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 23:58
End of Day Share Price2020/09/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.